2025年辽宁医药制造业增加值增长4.1% 迎发展机遇

Core Insights - The meeting highlighted significant advancements in Liaoning's pharmaceutical innovation and quality, with the province's pharmaceutical manufacturing value-added growth at 4.1%, surpassing both the provincial and national averages [1] - The internationalization of China's pharmaceuticals is accelerating, with projections indicating that by 2025, innovative drug licensing transactions will exceed $135 billion [1] - The pharmaceutical industry in Liaoning is positioned to support national strategies and improve public welfare while seizing opportunities for transformation and development [1] Summary by Sections Industry Development - Liaoning's pharmaceutical manufacturing value-added growth of 4.1% is notably higher than the provincial growth rate of 3.5% and the national rate of 1.7% [1] - The introduction of the first "Photon Counting CT" and the world's first "Cardiac Cryoablation Device" in Liaoning signifies a leap in medical technology [1] Regulatory Environment - The regulatory body aims to deepen reform, reduce burdens on enterprises, and stimulate innovation [1] - There is a commitment to strengthen legal frameworks to provide a fair and stable policy environment for businesses [1] Business Strategy - Liaoning's pharmaceutical companies are encouraged to focus on core competencies, innovate, and maintain integrity in operations to foster a fair market ecosystem [2] - Companies are urged to contribute to social welfare while pursuing high-quality development and achieving competitive advantages [2]